丙型肝炎病毒感染肝硬化患者肝移植前后抗病毒治疗

Effects of antiviral therapy in HCV-associated cirrhosis patients before and after liver transplantation

丙型肝炎病毒(HCV)相关肝脏疾病,尤其是在移植术前HCV RNA阳性的患者,移植术后HCV再感染的发生十分普遍,而且再感染一旦发生,肝脏损伤的进展较非移植患者明显增快。目前研究表明,移植术前HCV RNA阴性的患者移植术后发生HCV再感染的几率明显下降,移植术后发生HCV再感染后,有效的抗病毒治疗可阻止或延缓疾病的进展。本文就HCV感染肝硬化患者肝移植前后的抗病毒治疗作一综述。

Hepatitis C virus（HCV） recurrence is common after liver transplantation to resolve HCV-associated liver diseases.The rates of recurrence are especially high for patients who test positive for HCV RNA prior to the liver transplant procedure.The progression of liver injury is known to be more rapid in patients with HCV recurrence after liver transplantation than in patients before liver transplantation.Accumulating evidence indicates that the probability of HCV recurrence is decreased if HCV RNA is reduced to undetectable levels before liver transplantation and that effective antiviral therapy can prohibit or delay liver injury progression in patients with HCV recurrence after liver transplantation.This article reviews the current knowledge on effects of antiviral therapy in patients with HCV-associated cirrhosis before and after liver transplantation.